Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fleischmann, E. H.
Right arrow Articles by Weber, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fleischmann, E. H.
Right arrow Articles by Weber, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1825-1828
© 2002 European Renal Association-European Dialysis and Transplant Association

Brief Report

Active immunization against hepatitis A in dialysis patients

Erwin Hermann Fleischmann1, Johannes Kruppenbacher2, Hans Ludwig Bock3 and Manfred Weber4,

1 Medizinische Klinik IV der Universität Erlangen Nürnberg, 2 Virologisches Institut der Universität zu Köln, Germany, 3 GlaxoSmithKline Biologicals, Rixensart, Belgium and 4 Medizinische Klinik I, Kliniken der Stadt Köln, Medical Faculty, University of Cologne, Germany

Background. This study investigated the feasibility, immunogenicity, and reactogenicity of hepatitis A vaccination in end-stage renal failure patients who were on chronic intermittent haemodialysis.

Methods. Forty-three subjects were vaccinated with an inactivated hepatitis A vaccine according to a 0-, 1-, and 6-month immunization schedule. Two groups were established who received the vaccine either intramuscularly (group A, n=30) or subcutaneously (group B, n=13).

Results. All patients in group A and 12/13 in group B developed antibodies against hepatitis A. The geometric mean titres (GMT) were high and similar to those observed in healthy subjects. There was a tendency to higher GMT in the group who received the vaccine subcutaneously. No clinically significant adverse events were observed, and the liver enzyme profile showed no abnormalities.

Conclusions. We showed that hepatitis A vaccination of dialysis patients is feasible, well tolerated and immunogenic and that the vaccine can be given subcutaneously in those patients where intramuscular administration is contra-indicated.

Keywords: dialysis patients; feasibility; hepatitis A; immunization; immunogenicity; reactogenicity

Correspondence and offprint requests to: Prof. Dr Manfred Weber, Medizinische Klinik I, Kliniken der Stadt Köln, Ostmerheimer Str. 200, 51058 Köln. Email: manfred.weber{at}uni-koeln.de


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Janus, L.-V. Vacher, S. Karie, E. Ledneva, and G. Deray
Vaccination and chronic kidney disease
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 800 - 807.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.